ARCHIVES

PD-1 Checkpoint Inhibitor Opdivo First to Demonstrate Survival Benefit in Phase III

This article is from The Cancer Letter archive.

Vol. 37 No. 11 | November 28, 2014

Download PDF Visit The Full Archive

Related Articles

Funding Opportunities

February 7, 2003

ACS Study Shows Reduced Mortality For Low T/N Brands

April 18, 1980

NCI To Offer Planning Grants for New Centers

November 9, 1990

Darbepoetin Didn’t Decrease Blood Transfusions, Lowered Overall Survival, Study Finds

April 27, 2007

Broder On FDA: Don’t Blame Them For Doing Their Jobs (They Have To Work At Parklawn)

September 27, 1991

Keytruda Granted Approval In Metastatic Melanoma

September 26, 2014